Search Results - "Cox, Gina"

miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis by Smith, Kristen M, Guerau-de-Arellano, Mireia, Costinean, Stefan, Williams, Jessica L, Bottoni, Arianna, Mavrikis Cox, Gina, Satoskar, Abhay R, Croce, Carlo M, Racke, Michael K, Lovett-Racke, Amy E, Whitacre, Caroline C

“…Th cell programming and function is tightly regulated by complex biological networks to prevent excessive inflammatory responses and autoimmune disease. The…”
Get full text

Macrophage migration inhibitory factor (MIF) is essential for inflammatory and neuropathic pain and enhances pain in response to stress by Alexander, Jessica K., Cox, Gina M., Tian, Jin-Bin, Zha, Alicia M., Wei, Ping, Kigerl, Kristina A., Reddy, Mahesh K., Dagia, Nilesh M., Sielecki, Theis, Zhu, Michael X., Satoskar, Abhay R., McTigue, Dana M., Whitacre, Caroline C., Popovich, Phillip G.

“…Stress and glucocorticoids exacerbate pain via undefined mechanisms. Macrophage migration inhibitory factor (MIF) is a constitutively expressed protein that is…”
Get full text

Effect of longer-term ofatumumab treatment on disability progression and brain volume change by Jeffrey, Cohen, Stephen, Hauser, Edward, Fox, Ronald, Zielman, Amin, Azmon, Jing, Xi, Gina Mavrikis, Cox, Derrick, Robertson, Heinz, Wiendl, Ludwig, Kappos

“…Confirmed disability worsening (CDW), progression independent of relapse activity (PIRA), relapse-as- sociated worsening (RAW), and brain volume change (BVC)…”
Get full text

small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease by Kithcart, Aaron P, Cox, Gina M, Sielecki, Thais, Short, Abigail, Pruitt, James, Papenfuss, Tracey, Shawler, Todd, Gienapp, Ingrid, Satoskar, Abhay R, Whitacre, Caroline C

“…Multiple sclerosis (MS) is a chronic, debilitating disease of the central nervous system (CNS) characterized by demyelination and axon loss. The…”
Get full text

Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation by Cox, Gina Mavrikis, Kithcart, Aaron P, Pitt, David, Guan, Zhen, Alexander, Jessica, Williams, Jessica L, Shawler, Todd, Dagia, Nilesh M, Popovich, Phillip G, Satoskar, Abhay R, Whitacre, Caroline C

“…Macrophage migration inhibitory factor (MIF) is a multipotent cytokine that is associated with clinical worsening and relapses in multiple sclerosis (MS)…”
Get full text

Memory cells specific for myelin oligodendrocyte glycoprotein (MOG) govern the transfer of experimental autoimmune encephalomyelitis by Williams, Jessica L, Kithcart, Aaron P, Smith, Kristen M, Shawler, Todd, Cox, Gina M, Whitacre, Caroline C

“…Abstract Multiple sclerosis (MS) is an inflammatory disease of the CNS mediated by CD4+ T cells directed against myelin antigens. Experimental autoimmune…”
Get full text

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND Study (P5-4.002) by Hua, Le, Bar-Or, Amit, Lublin, Fred, Meng, Xiangyi, Cox, Gina, Cree, Bruce, Fox, Robert

“…Abstract only…”
Get full text

Siponimod Stabilizes Physical Disability Scores in People Living With Secondary Progressive Multiple Sclerosis After 2 Years of Treatment: Analysis From the Novartis Global Managed Access Program (P8-3.010) by Cox, Gina Mavrikis, De Las Heras, Virginia, Ryan, Suzannah, Istrate, Roxana Oana, Ansari, Soudeh, Arnould, Sophie, Piani-Meier, Daniela

“…Abstract only…”
Get full text

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying as Hispanic from the Phase 3 EXPAND Study (P8-4.007) by Cohan, Stanley, Hua, Le, Bar-Or, Amit, Lublin, Fred, Meng, Xiangyi, Cox, Gina, Coyle, Patricia, Fox, Robert

“…Abstract only…”
Get full text

Safety and Tolerability of Conversion to Siponimod in Patients with Advancing Relapsing Multiple Sclerosis: A Subgroup Analysis by Race and Ethnicity of EXCHANGE Interim Data (P8-4.006) by Bar-Or, Amit, Weinstock-Guttman, Bianca, Mao-Draayer, Yang, Chinea, Angel, Cox, Gina, Cruz, Linda-Ali, Meng, Xiangyi, Cohan, Stanley

“…Abstract only…”
Get full text

Safety and Tolerability of Conversion to Siponimod With and Without Titration in Patients with Advancing Forms of Relapsing Multiple Sclerosis: Interim Results of the Phase 3b EXCHANGE Study (P7-4.007) by Bar-Or, Amit, Weinstock-Guttman, Bianca, Mao-Draayer, Yang, Cruz, Linda-Ali, Meng, Xiangyi, Cox, Gina, Cohan, Stanley

“…Abstract only…”
Get full text

Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change (S16.009) by Cohen, Jeffrey, Hauser, Stephen, Zielman, Ronald, Gupta, Ayan Das, Azmon, Amin, Xi, Jing, Cox, Gina Mavrikis, Robertson, Derrick, Wiendl, Heinz, Kappos, Ludwig

“…Abstract only…”
Get full text

Safety and Tolerability of Conversion to Siponimod in Patients with Relapsing Multiple Sclerosis: Interim Results of the EXCHANGE Study (4598) by Bar-Or, Amit, Weinstock-Guttman, Bianca, Mao-Draayer, Yang, Cox, Gina, Cruz, Linda-Ali, Meng, Xiangyi, Su, Wendy, Cohan, Stanley L.

“…Abstract only…”
Get full text

Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study by Vieira, Maria Cecilia, Conway, Devon, Cox, Gina Mavrikis, Peeples, Miranda, Bensimon, Arielle G., Macheca, Monica, Herrera, Vivian

“…Objective: Disease modifying therapies (DMTs) for multiple sclerosis (MS) aim to delay progression and reduce relapses. Evidence is limited on the comparative…”
Get full text

THE NATIONAL BASIN DELINEATION PROJECT by Arthur, Ami T., Cox, Gina M., Kuhnert, Nathan R., Slayter, David L., Howard, Kenneth W.

“…The National Basin Delineation Project (NBDP) was undertaken by the National Severe Storms Laboratory to define flash-flood-scale basin boundaries for the…”
Get full text

Time to treatment failure following initiation of fingolimod versus teriflunomide for the treatment of multiple sclerosis: a retrospective U.S. claims study (P1.372) by da Silva, Maria Cecilia Vieira, Conway, Devon, Cox, Gina, Signorovitch, James, Peeples, Miranda, Bensimon, Arielle, Herrera, Vivian

“…Abstract only…”
Get full text

2271 Safety and tolerability of conversion to siponimod with and without titration in patients with relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study by Simpson, Marion, Bar-Or, Amit, Weinstock-Guttman, Bianca, Mao-Draayer, Yang, Cruz, Linda-Ali, Cox, Gina Mavrikis, Cohan, Stanley L

“…ObjectivesEXCHANGE is a 6-month, open-label, single-arm trial of conversion to siponimod in patients with MS. Here we report interim analyses evaluating safety…”
Get full text

Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study by Hua, Le H, Bar-Or, Amit, Cohan, Stanley L, Lublin, Fred D, Coyle, Patricia K, Cree, Bruce AC, Meng, Xiangyi, Su, Wendy, Cox, Gina Mavrikis, Fox, Robert J

“…Older age and longer disease duration (DD) may impact the effectiveness of disease-modifying therapies in patients with multiple sclerosis (MS). Siponimod is a…”
Get full text

Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study by Mao-Draayer, Yang, Cohen, Jeffrey A, Bar-Or, Amit, Han, May H, Singer, Barry, Williams, Ian M, Meng, Xiangyi, Elam, Chelsea, Weiss, Jamie L, Cox, Gina Mavrikis, Ziehn, Marina, Cree, Bruce AC

“…Background Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully…”
Get full text

TGF‐β signaling via Smad4 drives IL‐10 production in effector Th1 cells and reduces T‐cell trafficking in EAE by Huss, David J., Winger, Ryan C., Cox, Gina Mavrikis, Guerau‐de‐Arellano, Mireia, Yang, Yuhong, Racke, Michael K., Lovett‐Racke, Amy E.

“…Effector Th1 cells perpetuate inflammatory damage in a number of autoimmune diseases, including MS and its animal model EAE. Recently, a self‐regulatory…”
Get full text